XML 98 R55.htm IDEA: XBRL DOCUMENT v3.25.4
Collaborative and Other Relationships (Tables)
 12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Co-promotion profit sharing formula Our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:
After LUNSUMIO Approval until the First Threshold Date37.5 %
After First Threshold Date until the Second Threshold Date35.0 %
After Second Threshold Date30.0 %
Revenues from anti-CD20 therapeutic programs
Revenue from anti-CD20 therapeutic programs is summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 For the Years Ended December 31,
(In millions)202520242023
Royalty revenue on sales of OCREVUS$1,414.9 $1,339.5 $1,266.2 
Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO420.2 392.0 409.4 
Other revenue from anti-CD20 therapeutic programs25.5 18.4 14.0 
Total revenue from anti-CD20 therapeutic programs$1,860.6 $1,749.9 $1,689.6 
Revenue from anti-CD20 therapeutic programs is summarized as follows:
 For the Years Ended December 31,
(In millions)202520242023
Royalty revenue on sales of OCREVUS$1,414.9 $1,339.5 $1,266.2 
Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO420.2 392.0 409.4 
Other revenue from anti-CD20 therapeutic programs25.5 18.4 14.0 
Total revenue from anti-CD20 therapeutic programs$1,860.6 $1,749.9 $1,689.6 
Summary of activity related to BAN2401 and Elenbecestat collaboration
A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:
 For the Years Ended December 31,
(In millions)202520242023
Total development expense incurred by the collaboration related to the advancement of LEQEMBI$253.1 $329.6 $371.9 
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our consolidated statements of income126.5 164.8 186.0 
Total sales and marketing expense incurred by the LEQEMBI Collaboration701.6 647.0 304.4 
Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income350.8 323.5 152.2 
Summary Of Activity Related To Collaboration
A summary of development expense related to the UCB collaboration agreement is as follows:
For the Years Ended December 31,
(In millions)202520242023
Total UCB collaboration development expense$79.9 $77.5 $60.7 
Biogen's share of the UCB collaboration development expense reflected in research and development expense in our consolidated statements of income39.9 38.7 30.3 
A summary of development and sales and marketing expense related to the Supernus collaboration is as follows:
For the Years Ended December 31,
(In millions)202520242023
Total Supernus collaboration development expense$2.7 $34.2 $176.7 
Biogen's share of the Supernus collaboration development expense reflected in research and development expense in our consolidated statements of income1.3 17.1 88.3 
Total sales and marketing expense incurred by the Supernus collaboration173.0 118.5 187.0 
Biogen's share of the Supernus collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our consolidated statements of income86.5 59.2 93.5 
A summary of development expense related to the Denali collaboration is as follows:
For the Years Ended December 31,
(In millions)202520242023
Total Denali collaboration development expense$44.1 $53.1 $65.0 
Biogen's share of the Denali collaboration development expense reflected in research and development expense in our consolidated statements of income26.5 31.9 39.0 
A summary of development expense related to the Stoke collaboration agreement is as follows:
(In millions)For the Year Ended December 31, 2025
Total Stoke collaboration development expense$39.4 
Biogen's share of the Stoke collaboration development expense reflected in research and development expense in our consolidated statements of income11.8